R&D Licence for Canada & Sales Beginning in Argentina
VANCOUVER, Nov. 6, 2019 /CNW/ - Harvest One Cannabis Inc.
("Harvest One" or the "Company") (TSX-V: HVT;
OTCQX: HRVOF) is pleased to provide an update on its wholly
owned subsidiary Satipharm Ltd. ("Satipharm") and its
proprietary CBD Gelpell® capsules.
Harvest One, through its wholly owned licensed producer United
Greeneries Ltd., has received permission from Health Canada to
import Satipharm's CBD Gelpell® capsules into Canada for research and development purposes.
This achievement allows Harvest One to begin compliance testing and
analysis for the Canadian market in anticipation of full-scale
production in Canada in 2020.
Harvest One is also pleased to announce that Satipharm's CBD
Gelpell® capsules are now available in Argentina for medical purposes, and our
initial shipment has been received by the first patient. In
March 2017, the Argentine Congress
approved a new medical cannabis law. This law authorises the import
of cannabis products for sufferers of refractory epilepsy for
patients with a doctor's prescription. Satipharm has signed an
agreement with FederalMed to manage the importation and
distribution of Satipharm's CBD Gelpell® capsules to patients.
"At Harvest One, we view the Satipharm CBD Gelpell® capsule as a
key part of our health, wellness, and self-care strategy and are
very excited to be taking the next step in bringing them to the
Canadian market. With this import permit, Harvest One can continue
the necessary preparations to bring this unique, effective product
to Canada," said Grant Froese, Chief Executive Officer of Harvest
One. "We are equally excited to have our first shipment of
Satipharm's CBD Gelpell® capsules to Argentina, which marks Harvest One's first
entry into South America. This
adds to our existing distribution which includes 2,000 stores in
the UK and Ireland, on-line sales
across the EU, and prescription sales in Australia."
Satipharm produces a CBD capsule using the propriety Gelpell®
process. These capsules take a different approach to other
cannabinoid pills currently on the market in Canada and internationally. Gelpell® capsules
contain full spectrum hemp extract CBD in seamless gelatine
beads. These microbeads, contained in a hard gastro-resistant
capsule, release the CBD in the small intestine and maximise the
delivery of CBD to the body. Manufactured in Switzerland, and GMP certified, every
Gelpell® capsule delivers a consistent dose
of cannabinoids.
Satipharm CBD Gelpell capsules have 3.5 times higher
bioavailability compared to standard CBD oils. This unique product
has undergone Stage I and Stage II clinical trials with the results
published in two peer-reviewed international medical journals. For
further details on the clinical trials, please visit our website;
https://www.harvestone.com/portfolio/satipharm/#clinical-trials
About Harvest One
Harvest One is a global cannabis company that develops and
provides innovative health, wellness, and self-care products to
consumers and patients in regulated markets around the world. The
Company's range of solutions is designed to enhance quality of
life. Shareholders have significant exposure to the entire cannabis
value chain through four wholly owned subsidiaries: United
Greeneries, a licensed producer; Satipharm (medical and
nutraceutical); and Dream Water Global and Delivra (CPG), and a
minority interest in Burb Cannabis (retail operations). For more
information, please visit www.harvestone.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words "could",
"intend", "expect", "believe", "will", "projected", "estimated" and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on the Company's current belief or
assumptions as to the outcome and timing of such future
events. Actual future results may differ
materially. The forward-looking information contained in this press
release is made as of the date hereof, and the Company is not
obligated to update or revise any forward-looking information,
whether as a result of new information, future events or otherwise,
except as required by applicable securities laws. Because of the
risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward-looking information. The
foregoing statements expressly qualify any forward-looking
information contained herein.
Neither TSX-V nor its Regulation Services Provider (as that
term is defined in the policies of the TSX-V) accept responsibility
for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/harvest-one-provides-satipharm-cbd-gelpell-update-300952502.html
SOURCE Harvest One Cannabis Inc.
